Akebia Therapeutics Inc (AKBA)
1.845
+0.16
(+9.17%)
USD |
NASDAQ |
Nov 04, 16:00
1.85
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Revenue (Quarterly): 43.65M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 43.65M |
| March 31, 2024 | 32.61M |
| December 31, 2023 | 56.20M |
| September 30, 2023 | 42.05M |
| June 30, 2023 | 56.38M |
| March 31, 2023 | 40.00M |
| December 31, 2022 | 55.78M |
| September 30, 2022 | 48.71M |
| June 30, 2022 | 126.36M |
| March 31, 2022 | 61.70M |
| December 31, 2021 | 57.68M |
| September 30, 2021 | 48.76M |
| June 30, 2021 | 52.91M |
| March 31, 2021 | 52.30M |
| December 31, 2020 | 56.04M |
| September 30, 2020 | 59.99M |
| Date | Value |
|---|---|
| June 30, 2020 | 90.14M |
| March 31, 2020 | 88.48M |
| December 31, 2019 | 69.56M |
| September 30, 2019 | 91.98M |
| June 30, 2019 | 100.80M |
| March 31, 2019 | 72.67M |
| December 31, 2018 | 59.85M |
| September 30, 2018 | 53.17M |
| June 30, 2018 | 48.79M |
| March 31, 2018 | 45.93M |
| December 31, 2017 | 90.56M |
| September 30, 2017 | 41.28M |
| June 30, 2017 | 28.52M |
| March 31, 2017 | 20.86M |
| December 31, 2016 | 1.535M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
32.61M
Minimum
Mar 2024
126.36M
Maximum
Jun 2022
59.96M
Average
56.04M
Median
Dec 2020
Revenue (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 182.55M |
| Bioventus Inc | 151.22M |
| Eli Lilly and Co | 11.44B |
| NovaBay Pharmaceuticals Inc | 2.40M |
| Palatin Technologies Inc | 0.35M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.582M |
| Total Expenses (Quarterly) | 52.37M |
| EPS Diluted (Quarterly) | -0.04 |
| Enterprise Value | 386.51M |
| Gross Profit Margin (Quarterly) | 60.94% |
| Profit Margin (Quarterly) | -19.66% |
| Earnings Yield | -11.21% |
| Normalized Earnings Yield | -11.58 |